Table.

Research Priorities

1.	Development of new outcome measures that better capture the patient perspective on clinical status on all aspects of disease and its treatment, including impact of non-oral routes of administration and side effects
2.	Development of biomarkers that fit for purpose with a well-defined context of use
3.	Updating international consensus guidelines for the treatment of myasthenia to help guide clinicians’ use of new (and typically very expensive) therapeutic agents
4.	Development and widespread dissemination of electronic health record tools to permit collection of structured data at the point of clinical care
5.	Generation of health economic data that captures both the direct costs of therapies as well as the potential fiscal savings accrued through a reduction in the frequency and severity of side effects